Clinical Trial Update: Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale [Phase 3]

View source ↗

Summary

Phase 3 study assessing pharmacokinetics and safety of rFVIIIFc produced at 15,000 L scale for severe hemophilia A.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• rFVIIIFc (recombinant factor VIII Fc fusion protein)

Snippet

Sponsor: Bioverativ Therapeutics Inc. | Conditions: Severe Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2018-04-06